



Children's Mercy Hospitals & Clinics - 2023 Antibigram

Department of Pathology & Laboratory Medicine- Microbiology Laboratory

Gram Negative Antibigram (%susceptible)

Organism	# of isolates tested	Amikacin <sup>1</sup>	Ampicillin	Amp/sulbactam <sup>1</sup>	Cefazolin	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Gentamicin	Meropenem <sup>1</sup>	Pip/tazo	Tobramycin	Trimeth/Sulfa
<i>Acinetobacter baumannii</i> complex (includes <b>ALL</b> sources)	22 <sup>2</sup>	-	-	89	-	-	86	32	95	82	95	-	-	86
<i>Citrobacter freundii</i> (includes <b>ALL</b> sources)	25 <sup>2</sup>	-	IR	IR	IR	-	95	95	100	100	100	-	-	91
<i>Klebsiella aerogenes</i> <sup>^</sup> (includes <b>ALL</b> sources)	25 <sup>2</sup>	100	IR	IR	IR	100	94	94	100	96	100	-	-	100
<i>Serratia marcescens</i> (includes <b>ALL</b> sources)	62	-	IR	IR	IR	100	100	98	100	100	100	-	-	98
<i>Enterobacter cloacae</i> (Non-urine sources <b>ONLY</b> )	58	100	IR	IR	IR	100 <sup>b</sup>	-	100 <sup>2</sup>	100	96	100	-	-	98
<i>Pseudomonas aeruginosa</i> (Non-Urine sources <b>ONLY</b> )	200	-	-	-	-	77 <sup>2</sup>	96	-	92	-	95	87	-	-
* <i>Escherichia coli</i> (Non-Urine sources <b>ONLY</b> )	84	100	51	-	62 <sup>a</sup>	88 <sup>b</sup>	88	88	89	90	100	99	-	78
<i>Klebsiella oxytoca</i> (Non-Urine sources <b>ONLY</b> )	43	100	IR	-	24 <sup>a</sup>	94 <sup>b</sup>	95	92	95	95	100	-	-	92
* <i>Klebsiella pneumoniae</i> (Non-Urine sources <b>ONLY</b> )	43	100	IR	50 <sup>2</sup>	67 <sup>a</sup>	94 <sup>b</sup>	93	93	91	93	100	95	-	93
* <i>Proteus mirabilis</i> (Non-Urine sources <b>ONLY</b> )	12 <sup>2</sup>	-	83	-	17 <sup>a</sup>	100 <sup>b</sup>	100	100	100	100	100	-	-	90

ESBL positive isolates: *E. coli* (9), *K. pneumoniae* (4), *K. oxytoca* (0)

<sup>^</sup> *Klebsiella aerogenes*, formerly named *Enterobacter aerogenes*.

<sup>1</sup> Antibiotics tested on Non-Urine isolates only: *A. baumannii* complex (18), *K. aerogenes* (9).

<sup>2</sup> Please exercise discretion when data are reviewed for species with fewer than 30 isolates.

<sup>a</sup> Cefazolin susceptibility based off Kirby Bauer results.

<sup>b</sup> Cefepime susceptibility based off Kirby Bauer results.

IR = Intrinsic Resistance, (-) = No data available

\**E. coli*, *K. pneumoniae* and *P. mirabilis* breakpoints differ for urine culture vs. cultures from all other sources. Please contact the Microbiology laboratory for more information.



# Children's Mercy KANSAS CITY

## Children's Mercy Hospitals & Clinics - 2023 Antibigram

### Department of Pathology & Laboratory Medicine- Microbiology Laboratory

#### Gram Negative - URINE ONLY- Antibigram (% susceptible)

Organism	# of isolates tested	Ampicillin	Amox/clav	Cefazolin	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Gentamicin	Nitrofurantoin	Tobramycin	Trimeth/Sulfa
<i>Enterobacter cloacae</i>	41	IR	IR	IR	-	83	81	98	100	45	-	89
<i>Pseudomonas aeruginosa</i>	68	-	-	-	100	96	-	99	-	-	-	-
* <i>Escherichia coli</i>	1441	54	66	92	-	96	96	91	91	98	-	76
<i>Klebsiella oxytoca</i>	56	IR	93	27	-	100	95	100	100	95	-	92
* <i>Klebsiella pneumoniae</i>	109	IR	96	94	-	98	98	97	96	25	-	93
* <i>Proteus mirabilis</i>	104	88	100	98	-	99	100	100	97	IR	-	90

ESBL positive isolates: *E. coli* (66), *K. pneumoniae* (3), *K. oxytoca* (0)

IR = Intrinsic Resistance, (-) = No data available

\**E. coli*, *K. pneumoniae* and *P. mirabilis* breakpoints differ for urine culture vs. cultures from all other sources. Please contact the Microbiology laboratory for more information.



Children's Mercy Hospitals & Clinics - 2023 Antibigram

Department of Pathology & Laboratory Medicine- Microbiology Laboratory

Gram Positive Antibigram (% Susceptible)

Organism	# of isolates tested	Ampicillin	Cefotaxime	Clindamycin	Erythromycin	Gentamicin <sup>3</sup>	Linezolid	Meropenem	Nitrofurantoin <sup>4</sup>	Oxacillin	Penicillin	Penicillin (Oral)	Rifampin <sup>a</sup>	Tetracycline	Trim/Sulfa	Vancomycin
<i>Enterococcus faecalis</i>	197	99	-	-	-	-	-	-	100	-	99	-	-	-	-	100
All <i>Staphylococcus aureus</i>	1177	-	-	81	56	-	100	-	100	72	0	-	100	93	94	100
MSSA	852	-	-	79	68	-	100	-	100	100	0	-	100	95	96	100
MRSA	325	-	-	85	26	-	100	-	100	0	0	-	100	89	88	100
<i>Staphylococcus epidermidis</i>	123	-	-	52	28	-	100	-	100	33	0	-	99	85	58	100
<i>S. pneumoniae</i> *	64	-	-	88	58	-	-	93	-	-	-	64 <sup>§</sup>	-	-	-	100
Meningitis breakpoint		-	89 <sup>†</sup>	-	-	-	-	-	-	-	67 <sup>†</sup>	-	-	-	-	-
Non-meningitis breakpoint		-	98 <sup>‡</sup>	-	-	-	-	-	-	-	95 <sup>†</sup>	-	-	-	-	-

\* *S. pneumoniae* % susceptible was calculated using all isolates based on meningitis, nonmeningitis and oral breakpoints.

# of *S.pneumoniae* isolates tested: Penicillin=64, Cefotaxime=64, Erythromycin=50, Clindamycin=64, Meropenem=14, Vancomycin=14

<sup>†</sup> Susceptible breakpoint for *S. pneumoniae* in patients with meningitis is  $\leq 0.5 \mu\text{g/mL}$  for cefotaxime and  $\leq 0.06 \mu\text{g/mL}$  for penicillin

<sup>‡</sup> Susceptible breakpoint for *S. pneumoniae* in patients with non-meningitis infections is  $\leq 1\mu\text{g/mL}$  for cefotaxime and  $\leq 2 \mu\text{g/mL}$  for penicillin

<sup>§</sup> Susceptible breakpoint for *S. pneumoniae* is  $\leq 0.06 \mu\text{g/mL}$  for penicillin when penicillin V is administered by the oral route

<sup>3</sup> Used only in combination for synergy and is not adequate therapy by itself.

<sup>4</sup> Antibiotics tested on UTI isolates only: *E. faecalis* (166), *S. aureus* (45), *S. epidermidis* (53)

(-) =No data available